8-K: Chrome Holding Co. Files August Bankruptcy Report

Chrome Holding Co. (formerly 23andMe Holding Co.) filed its August 2025 monthly operating report, detailing financial activities and ongoing Chapter 11 proceedings, including asset sales and a significant net loss.

Summary

• Chrome Holding Co. (formerly 23andMe Holding Co.) and its subsidiaries are operating under Chapter 11 bankruptcy protection, initiated on March 23, 2025.
• The company filed its Monthly Operating Report for the period ended August 31, 2025, with the U.S. Bankruptcy Court for the Eastern District of Missouri.
• A consolidated net loss of $11.982 million was reported for August 2025.
• Total consolidated revenue for August 2025 was $1.716 million, comprising $1.449 million from product revenue and $0.267 million from consumer services revenue.
• Consolidated cash and cash equivalents stood at $282.996 million as of August 31, 2025, with a beginning bank cash balance of $292.755 million and an ending balance of $281.812 million for the month.
• The company completed the sale of substantially all its assets to 23andMe Research Institute on July 14, 2025.
• A Stock Purchase Agreement for the sale of the Lemonaid telehealth business was entered into on September 10, 2025, subject to Court approval through the Debtors' Plan.
• The Debtors have filed their First Amended Joint Chapter 11 Plan and Disclosure Statement, with the Disclosure Statement approved by the Court on September 25, 2025.
• The company reported 0 full-time employees, both currently and as of the petition date, reflecting its post-sale, bankruptcy operational status.

Sentiment

Score: 2

Explanation: The company is in Chapter 11 bankruptcy, reported a significant net loss, has effectively ceased operations with 0 employees, and explicitly warns investors about the high risks and potential lack of recovery for common stock. While there is progress in the bankruptcy process (plan filed, disclosure approved, asset sales), the overall financial health and outlook for equity holders are extremely negative.

Positives

• The company is actively progressing through its Chapter 11 cases, with a Plan and Disclosure Statement filed and the Disclosure Statement approved by the Court.
• The sale of substantially all assets to 23andMe Research Institute was completed on July 14, 2025, and a Stock Purchase Agreement for the Lemonaid telehealth business was entered into, indicating progress in asset disposition.
• The company successfully repaid its Debtor-in-Possession (DIP) financing on July 14, 2025, demonstrating liquidity to cover post-petition obligations.
• The company is current on postpetition tax return filings, estimated tax payments, and trust fund taxes, and all required insurance premiums are current.

Negatives

• The company is currently operating under Chapter 11 bankruptcy protection, indicating severe financial distress.
• A consolidated net loss of $11.982 million was reported for August 2025.
• The company reported 0 full-time employees, reflecting a significant reduction in operations post-asset sales.
• The company explicitly cautions that trading in its Class A common stock is highly speculative and poses substantial risks, with trading prices potentially bearing little or no relationship to actual recovery for common stock holders.
• The Monthly Operating Report is unaudited, not prepared in accordance with GAAP, and not intended for investment decisions, highlighting limitations in financial transparency and reliability for investors.

Risks

• Risks and uncertainties relating to the Chapter 11 Cases, including the company's ability to obtain Court approval for motions, the effects of the cases on the company and constituents, Court rulings, and the outcome of the cases.
• The length of time the company will operate under Chapter 11.
• Risks associated with any third-party motions in the Chapter 11 Cases.
• Adverse effects of the Chapter 11 Cases on the company's liquidity or results of operations and increased legal and other professional costs.
• Trading in the company's Class A common stock is highly speculative and poses substantial risks, with trading prices potentially bearing little or no relationship to the actual recovery, if any, by holders of the Common Stock.
• No assurance of the liquidity of an active trading market for the Common Stock, the ability to sell shares when desired, or the prices that an investor may obtain.
• The financial information in the Monthly Operating Report is unaudited, not GAAP-compliant, limited in scope, and subject to future adjustment and material change, making it unreliable for investment decisions.

Future Outlook

The company will continue to file monthly operating reports with the Court as long as the Chapter 11 Cases remain pending. The sale of the Lemonaid telehealth business is subject to Court approval through the Debtors' Plan. The company cautions that forward-looking statements involve risks and uncertainties, and actual results may differ materially from expectations, particularly concerning the Chapter 11 Cases and the trading of its common stock.

Management Comments

• Trading in the Company's Class A common stock... is highly speculative and poses substantial risks.
• Trading prices for the Company's Common Stock may bear little or no relationship to the actual recovery, if any, by holders of the Common Stock in the Chapter 11 Cases.
• The Company cannot assure investors of the liquidity of an active trading market, the ability to sell shares of the Common Stock when desired, or the prices that an investor may obtain for the shares of the Common Stock.
• The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Monthly Operating Report, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company.
• The Debtors believe that the financial information may be subject to change, and these changes could be material.
• There can be no assurance that, from the perspective of an investor or potential investor in the Company's securities, the Monthly Operating Report is complete.
• Results and projections set forth in the Monthly Operating Report should not be viewed as indicative of future results.

Industry Context

This filing reflects a company undergoing significant restructuring through Chapter 11 bankruptcy, a process typically undertaken by companies facing severe financial distress. The sale of substantially all assets and the planned sale of the Lemonaid telehealth business indicate a strategic shift away from previous business models, likely due to unprofitability or unsustainable operations. The reduction to zero employees suggests a near-complete cessation of direct operational activities, with the remaining entity focused on managing the bankruptcy process and asset disposition. This contrasts sharply with healthy companies in the biotechnology or telehealth sectors that are actively growing and investing in R&D and market expansion.

Corporate Governance

Legal Proceedings

• The company is currently undergoing Chapter 11 bankruptcy proceedings in the United States Bankruptcy Court for the Eastern District of Missouri (Case No. 25-40976-357).
• The Debtors are involved in ancillary proceedings in the Supreme Court of British Columbia in Vancouver, British Columbia, pursuant to the Companies Creditors Arrangement Act, R.S.C. 1985, c. C-36, where Matthew Kvarda acts as Foreign Representative.

Stakeholder Impact

• Shareholders: Common stock holders face substantial risks, with trading being highly speculative and little to no assurance of recovery in the Chapter 11 Cases. The company explicitly warns against undue reliance on the stock's trading price.
• Creditors: Unsecured creditors have an official committee appointed to represent their interests in the Chapter 11 proceedings.
• Employees: The company reported 0 full-time employees, indicating a significant impact on its workforce due to asset sales and bankruptcy.
• Customers: The sale of the Lemonaid telehealth business, subject to court approval, will impact customers of those services, likely transferring them to the new owner.

Next Steps

• The Debtors will continue to file monthly operating reports with the Court at or around the end of each month during which the Chapter 11 Cases remain pending.
• The Lemonaid Sale remains subject to Court approval through the Debtors' Plan.
• The Court will rule on the confirmation of the relevant proposed Chapter 11 plan.

Key Dates

Recommendation

The company is in Chapter 11 bankruptcy, has sold substantially all its assets, reported a significant net loss, and has 0 employees. Management explicitly warns that common stock trading is highly speculative and may bear little to no relationship to actual recovery for shareholders. The financial statements are unaudited and not GAAP-compliant, further increasing risk. For a seasoned investor, the risk of total loss for equity holders is extremely high, warranting a strong sell recommendation or avoidance.

Keywords

Chapter 11, Bankruptcy, Monthly Operating Report, Asset Sale, 23andMe Holding Co., Chrome Holding Co., Lemonaid Health, DIP Financing, Reorganization Plan, SEC Filing, Financial Distress, Corporate Restructuring